Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients. 31719050

2020

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. 30709841

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE In the multivariate analysis, serum p53 antibody level was an independent predictor of OS in mCRC patients (high vs. normal; hazard ratio 0.438, 95% confidence interval 0.178-0.974, p < 0.05). 31834556

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Therefore we evaluated the combined impact of sidedness and TP53 mutation status in the anti-EGFR treated cohort and patients with left-sided/TP53 wild-type mCRC showed the longest median OS (38.9 months) of all groups (right-sided/TP53 mutant: 12.1 months; right-sided/TP53 wild-type: 8.9 months; left-sided/TP53 mutant: 18.4 months; p = 0.020). 29298682

2018

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Aberrant O-linked glycosylation was observed to be an early event that occurred irrespective of the p53 and KRAS status and correlating with metastatic colorectal cancer. 26495974

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE This study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy. 26490659

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. 25337237

2014

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. 25474278

2014

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Therefore, whether or not the combined mutation status of KRAS and TP53 could predict response to chemotherapy in metastatic colorectal cancer was tested. 21508389

2011

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE To investigate three genetic alterations (TP53 mutation, Kras mutation and microsatellite instability (MSI)) and three polymorphisms (methylene tetrahydrofolate reductase (MTHFR) C677T, excision repair cross complementing group 1 (ERCC1)-118 and X-ray repair cross complementing group 1 (XRCC1)-399) for their ability to predict response, survival and toxicity to FOLFOX first line chemotherapy in the treatment of metastatic colorectal cancer (mCRC). 19672255

2009

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. 19367287

2009

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE As part of a Phase I study, we evaluated biological responses to a replication-defective adenovirus encoding the p53 transgene (SCH 58500) when administered by hepatic arterial infusion to patients with primarily colorectal cancer metastatic to the liver. 16082381

2006

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE We did not find a statistically significant relationship between mutations of k-ras, b-raf, or p53 and the increase in median survival associated with the addition of bevacizumab to IFL in metastatic colorectal cancer. 15998951

2005

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. 12065560

2002

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE To establish the relationship between the number and site of p53 genomic mutations in metastatic colorectal cancer, and the response to hepatic arterial floxuridine. 11710597

2001